Crescendo Biologics announces first U.S. patients dosed in expanded Phase 1b clinical trial of CB307 for patients with mCRPC Crescendo expands trial of lead programme first-in-class, bispecific ...
SAN FRANCISCO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- CRESCENDO LIVE: SF -- Crescendo, the first AI-native contact center, today announced the launch of Multimodal AI, representing an industry-first ...
Martin Jacobson of Newport, Rhode Island drove his Swan 44 MkII Crescendo first across the line off St. David’s Lighthouse, Bermuda Wednesday morning (June 24) at 5:47:13 ADT with an elapsed time of ...
Customers can now simultaneously interact through voice, text, and with visuals, in the same conversation SAN FRANCISCO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- CRESCENDO LIVE: SF -- Crescendo, the first AI ...
Crescendo expands trial of lead programme first-in-class, bispecific Humabody®, CB307 beyond Europe with first US trial site, the Fred Hutchinson Cancer Centre, at the University of Washington ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback